Characterization of β-Lactamases Responsible for Resistance to Extended-Spectrum Cephalosporins in Escherichia coli and Salmonella enterica Strains from Food-Producing Animals in the United Kingdom

Ernesto Liebana, Matthew Gibbs, Carol Clouting, Leslie Barker, Felicity A. Clifton-Hadley, Eve Pleydell, Baha Abdalhamid, Nancy D. Hanson, Laura Martin, Cornelius Poppe, Rob H. Davies

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Nine epidemiologically unrelated isolates {1 Salmonella Bredeney from turkeys, and 8 Escherichia coli [3 environmental isolates (2 from chickens, 1 from pigs), and 5 isolates from cattle with neonatal diarrhea]} were examined both pheno- and genotypically for extended-spectrum β-lactam (ESBL) resistance. Resistance phenotypes (ampicillin, aztreonam, cefotaxime, cefpodoxime, ceftazidime, and ceftriaxone) suggested the presence of an ESBL enzyme, but cefoxitin MICs (≥ 32 mg/L) suggested the presence of an AmpC-like enzyme. Synergism experiments with benzo(b)thiophene-2-boronic acid (BZBTH2B) and isoelectric focusing (IEF) revealed the presence of an AmpC β-lactamase with a pI ≥ 9. ampC multiplex PCR, sequence, and Southern analyses indicated that only the Salmonella isolate had a plasmid-encoded AmpC β-lactamase CMY-2 on a nonconjugative 60-MDa plasmid. PCR and sequence analysis of the E. coli ampC promoter identified mutations at positions -88(T), -82(G), -42(T), -18(A), -1(T) and +58(T) in all the isolates. In addition one strain had two extra-mutations at positions +23(A) and +49(G), and another strain had one extra-mutation at position +32(A). DNA fingerprinting revealed that all the E. coli isolates were different clones. It also showed that the U.K. Salmonella isolate was indistinguisable from a Canadian Salmonella isolate from turkeys; both had identical resistance phenotypes and produced CMY-2. This is the first report of a CMY-2 Salmonella isolate in the United Kingdom. These data imply that β-lactam resistance in animal isolates can be generated de novo as evidenced by the E. coli strains, or in the case of the Salmonella strains be the result of intercontinental transmission due to an acquired resistance mechanism.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalMicrobial Drug Resistance
Volume10
Issue number1
DOIs
StatePublished - Mar 2004

Fingerprint

Salmonella enterica
Cephalosporins
Salmonella
Escherichia coli
Food
Lactams
cefpodoxime
Mutation
Sequence Analysis
Plasmids
Ampicillin Resistance
Phenotype
Aztreonam
Cefoxitin
Ceftazidime
Cefotaxime
DNA Fingerprinting
Ceftriaxone
Multiplex Polymerase Chain Reaction
Isoelectric Focusing

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology
  • Immunology
  • Microbiology

Cite this

Characterization of β-Lactamases Responsible for Resistance to Extended-Spectrum Cephalosporins in Escherichia coli and Salmonella enterica Strains from Food-Producing Animals in the United Kingdom. / Liebana, Ernesto; Gibbs, Matthew; Clouting, Carol; Barker, Leslie; Clifton-Hadley, Felicity A.; Pleydell, Eve; Abdalhamid, Baha; Hanson, Nancy D.; Martin, Laura; Poppe, Cornelius; Davies, Rob H.

In: Microbial Drug Resistance, Vol. 10, No. 1, 03.2004, p. 1-9.

Research output: Contribution to journalArticle

Liebana, Ernesto ; Gibbs, Matthew ; Clouting, Carol ; Barker, Leslie ; Clifton-Hadley, Felicity A. ; Pleydell, Eve ; Abdalhamid, Baha ; Hanson, Nancy D. ; Martin, Laura ; Poppe, Cornelius ; Davies, Rob H. / Characterization of β-Lactamases Responsible for Resistance to Extended-Spectrum Cephalosporins in Escherichia coli and Salmonella enterica Strains from Food-Producing Animals in the United Kingdom. In: Microbial Drug Resistance. 2004 ; Vol. 10, No. 1. pp. 1-9.
@article{555326eae0f24dc48a62acf9bd31d8fb,
title = "Characterization of β-Lactamases Responsible for Resistance to Extended-Spectrum Cephalosporins in Escherichia coli and Salmonella enterica Strains from Food-Producing Animals in the United Kingdom",
abstract = "Nine epidemiologically unrelated isolates {1 Salmonella Bredeney from turkeys, and 8 Escherichia coli [3 environmental isolates (2 from chickens, 1 from pigs), and 5 isolates from cattle with neonatal diarrhea]} were examined both pheno- and genotypically for extended-spectrum β-lactam (ESBL) resistance. Resistance phenotypes (ampicillin, aztreonam, cefotaxime, cefpodoxime, ceftazidime, and ceftriaxone) suggested the presence of an ESBL enzyme, but cefoxitin MICs (≥ 32 mg/L) suggested the presence of an AmpC-like enzyme. Synergism experiments with benzo(b)thiophene-2-boronic acid (BZBTH2B) and isoelectric focusing (IEF) revealed the presence of an AmpC β-lactamase with a pI ≥ 9. ampC multiplex PCR, sequence, and Southern analyses indicated that only the Salmonella isolate had a plasmid-encoded AmpC β-lactamase CMY-2 on a nonconjugative 60-MDa plasmid. PCR and sequence analysis of the E. coli ampC promoter identified mutations at positions -88(T), -82(G), -42(T), -18(A), -1(T) and +58(T) in all the isolates. In addition one strain had two extra-mutations at positions +23(A) and +49(G), and another strain had one extra-mutation at position +32(A). DNA fingerprinting revealed that all the E. coli isolates were different clones. It also showed that the U.K. Salmonella isolate was indistinguisable from a Canadian Salmonella isolate from turkeys; both had identical resistance phenotypes and produced CMY-2. This is the first report of a CMY-2 Salmonella isolate in the United Kingdom. These data imply that β-lactam resistance in animal isolates can be generated de novo as evidenced by the E. coli strains, or in the case of the Salmonella strains be the result of intercontinental transmission due to an acquired resistance mechanism.",
author = "Ernesto Liebana and Matthew Gibbs and Carol Clouting and Leslie Barker and Clifton-Hadley, {Felicity A.} and Eve Pleydell and Baha Abdalhamid and Hanson, {Nancy D.} and Laura Martin and Cornelius Poppe and Davies, {Rob H.}",
year = "2004",
month = "3",
doi = "10.1089/107662904323047745",
language = "English",
volume = "10",
pages = "1--9",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Characterization of β-Lactamases Responsible for Resistance to Extended-Spectrum Cephalosporins in Escherichia coli and Salmonella enterica Strains from Food-Producing Animals in the United Kingdom

AU - Liebana, Ernesto

AU - Gibbs, Matthew

AU - Clouting, Carol

AU - Barker, Leslie

AU - Clifton-Hadley, Felicity A.

AU - Pleydell, Eve

AU - Abdalhamid, Baha

AU - Hanson, Nancy D.

AU - Martin, Laura

AU - Poppe, Cornelius

AU - Davies, Rob H.

PY - 2004/3

Y1 - 2004/3

N2 - Nine epidemiologically unrelated isolates {1 Salmonella Bredeney from turkeys, and 8 Escherichia coli [3 environmental isolates (2 from chickens, 1 from pigs), and 5 isolates from cattle with neonatal diarrhea]} were examined both pheno- and genotypically for extended-spectrum β-lactam (ESBL) resistance. Resistance phenotypes (ampicillin, aztreonam, cefotaxime, cefpodoxime, ceftazidime, and ceftriaxone) suggested the presence of an ESBL enzyme, but cefoxitin MICs (≥ 32 mg/L) suggested the presence of an AmpC-like enzyme. Synergism experiments with benzo(b)thiophene-2-boronic acid (BZBTH2B) and isoelectric focusing (IEF) revealed the presence of an AmpC β-lactamase with a pI ≥ 9. ampC multiplex PCR, sequence, and Southern analyses indicated that only the Salmonella isolate had a plasmid-encoded AmpC β-lactamase CMY-2 on a nonconjugative 60-MDa plasmid. PCR and sequence analysis of the E. coli ampC promoter identified mutations at positions -88(T), -82(G), -42(T), -18(A), -1(T) and +58(T) in all the isolates. In addition one strain had two extra-mutations at positions +23(A) and +49(G), and another strain had one extra-mutation at position +32(A). DNA fingerprinting revealed that all the E. coli isolates were different clones. It also showed that the U.K. Salmonella isolate was indistinguisable from a Canadian Salmonella isolate from turkeys; both had identical resistance phenotypes and produced CMY-2. This is the first report of a CMY-2 Salmonella isolate in the United Kingdom. These data imply that β-lactam resistance in animal isolates can be generated de novo as evidenced by the E. coli strains, or in the case of the Salmonella strains be the result of intercontinental transmission due to an acquired resistance mechanism.

AB - Nine epidemiologically unrelated isolates {1 Salmonella Bredeney from turkeys, and 8 Escherichia coli [3 environmental isolates (2 from chickens, 1 from pigs), and 5 isolates from cattle with neonatal diarrhea]} were examined both pheno- and genotypically for extended-spectrum β-lactam (ESBL) resistance. Resistance phenotypes (ampicillin, aztreonam, cefotaxime, cefpodoxime, ceftazidime, and ceftriaxone) suggested the presence of an ESBL enzyme, but cefoxitin MICs (≥ 32 mg/L) suggested the presence of an AmpC-like enzyme. Synergism experiments with benzo(b)thiophene-2-boronic acid (BZBTH2B) and isoelectric focusing (IEF) revealed the presence of an AmpC β-lactamase with a pI ≥ 9. ampC multiplex PCR, sequence, and Southern analyses indicated that only the Salmonella isolate had a plasmid-encoded AmpC β-lactamase CMY-2 on a nonconjugative 60-MDa plasmid. PCR and sequence analysis of the E. coli ampC promoter identified mutations at positions -88(T), -82(G), -42(T), -18(A), -1(T) and +58(T) in all the isolates. In addition one strain had two extra-mutations at positions +23(A) and +49(G), and another strain had one extra-mutation at position +32(A). DNA fingerprinting revealed that all the E. coli isolates were different clones. It also showed that the U.K. Salmonella isolate was indistinguisable from a Canadian Salmonella isolate from turkeys; both had identical resistance phenotypes and produced CMY-2. This is the first report of a CMY-2 Salmonella isolate in the United Kingdom. These data imply that β-lactam resistance in animal isolates can be generated de novo as evidenced by the E. coli strains, or in the case of the Salmonella strains be the result of intercontinental transmission due to an acquired resistance mechanism.

UR - http://www.scopus.com/inward/record.url?scp=11144354937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354937&partnerID=8YFLogxK

U2 - 10.1089/107662904323047745

DO - 10.1089/107662904323047745

M3 - Article

VL - 10

SP - 1

EP - 9

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 1

ER -